SCHEDULE: T. Rowe Price Discloses 14.5% Stake in Immunome Inc.

T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 14.5% in Immunome Inc. as of March 31, 2026.

Summary

• T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, indicating a significant ownership stake in Immunome Inc.
• The filing, dated March 31, 2026, shows beneficial ownership of 16,364,011 shares of Immunome Inc.'s common stock.
• This represents 14.5% of the total class of securities.
• T. Rowe Price Investment Management, Inc. has sole voting power over 16,346,000 shares and sole dispositive power over 16,364,011 shares.
• The filing clarifies that T. Rowe Price Investment Management, Inc. acts as an investment adviser, and ultimate control over dividends and sale proceeds rests with its clients.
• Specifically, T. ROWE PRICE SMALL-CAP STOCK FUND holds 5,764,704 shares, representing 5.2% of the class.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the significant stake taken by a major institutional investor, indicating confidence in Immunome Inc.'s future prospects.

Positives

• T. Rowe Price Investment Management, Inc., a significant institutional investor, has taken a substantial stake in Immunome Inc., suggesting confidence in the company's prospects.
• The disclosure of a 14.5% ownership by a reputable investment firm can be seen as a positive signal to the market.
• The T. ROWE PRICE SMALL-CAP STOCK FUND's specific holding of 5.2% indicates a focused investment within a managed portfolio.

Negatives

• The filing does not contain any negative financial results or operational challenges for Immunome Inc. itself, as it is a disclosure of ownership by an external entity.

Risks

• As T. Rowe Price Investment Management, Inc. is an investment adviser, the ultimate control of dividends and sale proceeds lies with its clients, introducing a layer of indirect control.
• Any discretionary authority delegated to T. Rowe Price Investment Management, Inc. by its clients can be revoked at any time, potentially impacting its investment position.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from Immunome Inc.

Management Comments

• T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• Ellen York, Vice President of T. Rowe Price Investment Management, Inc., certified that the information is true, complete, and correct.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by major investment firms like T. Rowe Price often signal a belief in the target company's growth potential, particularly in sectors like biotechnology where Immunome Inc. operates. This filing suggests increased institutional interest in Immunome Inc.

Stakeholder Impact

• Shareholders may view the increased institutional ownership positively, potentially leading to greater market interest and share price appreciation.
• The investment by T. Rowe Price could signal a more stable and scrutinized ownership structure for Immunome Inc.

Next Steps

• Continued monitoring of T. Rowe Price Investment Management's holdings and any further disclosures related to Immunome Inc.

Key Dates

Recommendation

While the increased institutional ownership is a positive signal, the filing is a disclosure of an existing stake by an investment manager and does not provide new operational or financial information about Immunome Inc. itself. Therefore, a 'hold' recommendation is appropriate pending further company-specific developments.

Keywords

Immunome Inc., T. Rowe Price Investment Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Investor, Securities Filing, T. Rowe Price Small-Cap Stock Fund